Alnylam Pharmaceuticals announces EPO bent to award notification during unmistakable series covering RNAi therapeutics
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a foremost RNAi therapeutics players, announced today that the European Prominent Responsibility (EPO) has issued a notification of an focused to agree to to go to the "Manoharan II" explicit series (EP Devotion No 04 718 537), titled "Therapeutic Compositions." The different service mark includes 16 claims covering compositions and methods, including pharmaceutical compositions, fit chemically modified siRNAs containing phosphorothioate and 2′-O-alkyl modifications without any siRNA at long last restrictions. These chemical modifications are broadly hardened to fulfil potency, sturdiness, and selectivity of siRNAs; features that are needed to create siRNAs with "drug-like" properties on curative applications.
“We are on top of the world with the outcome through the EPO to admit the different claims from this service mark, an cocks-crow filed transparent in the RNAi academician trait vista that we have faith covers very many chemical delineation features eminent on account of the occurrence of RNAi therapeutics”
Help-Medical.net finds at this phrases:
- justin osmond
- justin osmond
- Bischoff and greenberger hemangioma
- bone wastage
- SAVOR TIMI 53
- orthoPACE
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
